Duke Cancer Institute
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Duke Cancer Institute
Apr 17, 2024, 14:12 |
Drugs
Thomas LeBlanc: Cancer patients cannot afford to delay treatment due to drug shortages
Thomas LeBlanc, Chief Patient Experience and Safety Officer at Duke Cancer Institute, shared on X/Twitter:…
Feb 29, 2024, 05:15 |
Blog
Thomas LeBlanc: I signed ASCO’s letter to end the drug shortage crisis
Thomas LeBlanc, Chief Patient Experience and Safety Officer for the Duke Cancer Institute, shared on…
Feb 24, 2024, 16:28 |
Blog
Chenyu Lin: Thanks again to ASTCT for supporting our research in chronic GVHD
Chenyu Lin, Assistant Professor at the Duke Cancer Institute, shared a post by ASTCT on…
Dec 15, 2023, 06:25 |
Drugs
Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age
Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute,…
1
2
All:
14
Posts:
11 - 20
We need to hurry up, because cancer and patients cannot wait!
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Facebook
RSS Feed
Twitter
Linkedin
Youtube